Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

838 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
Schell M, Pflüger I, Brugnara G, Isensee F, Neuberger U, Foltyn M, Kessler T, Sahm F, Wick A, Nowosielski M, Heiland S, Weller M, Platten M, Maier-Hein KH, Von Deimling A, Van Den Bent MJ, Gorlia T, Wick W, Bendszus M, Kickingereder P. Schell M, et al. Among authors: von deimling a. Neuro Oncol. 2020 Nov 26;22(11):1667-1676. doi: 10.1093/neuonc/noaa120. Neuro Oncol. 2020. PMID: 32393964 Free PMC article. Clinical Trial.
TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA, Wenghoefer M, Glesmann N, Mohr S, Beck M, Schmidt MC, Schröder R, Berweiler U, Roggendorf W, Diete S, Dietzmann K, Heuser K, Müller B, Fimmers R, von Deimling A, Schlegel U. Kraus JA, et al. Among authors: von deimling a. J Neurooncol. 2001 May;52(3):263-72. doi: 10.1023/a:1010684203704. J Neurooncol. 2001. PMID: 11519857
No preferential loss of paternal 19q alleles in oligodendroglial tumors.
Hartmann C, Mueller W, Lass U, Stockhammer F, von Eckardstein K, Veelken J, Jeuken J, Wick W, von Deimling A. Hartmann C, et al. Among authors: von deimling a, von eckardstein k. Ann Neurol. 2003 Aug;54(2):256-8. doi: 10.1002/ana.10649. Ann Neurol. 2003. PMID: 12891681
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A. Hartmann C, et al. Among authors: von deimling a. Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25. Acta Neuropathol. 2009. PMID: 19554337 Free article.
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M. Weller M, et al. Among authors: von deimling a. J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805672 Free article.
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M, von Deimling A, Weller M, Wick W. Weiler M, et al. Among authors: von deimling a. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):670-6. doi: 10.1016/j.ijrobp.2009.05.031. Epub 2009 Oct 14. Int J Radiat Oncol Biol Phys. 2010. PMID: 19836157 Free article. Clinical Trial.
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M. Wick W, et al. Among authors: von deimling a. J Clin Oncol. 2009 Dec 10;27(35):5874-80. doi: 10.1200/JCO.2009.23.6497. Epub 2009 Nov 9. J Clin Oncol. 2009. PMID: 19901110 Clinical Trial.
Defective p53 antiangiogenic signaling in glioblastoma.
Berger B, Capper D, Lemke D, Pfenning PN, Platten M, Weller M, von Deimling A, Wick W, Weiler M. Berger B, et al. Among authors: von deimling a. Neuro Oncol. 2010 Sep;12(9):894-907. doi: 10.1093/neuonc/noq051. Epub 2010 May 26. Neuro Oncol. 2010. PMID: 20504876 Free PMC article.
Identification of diagnostic serum protein profiles of glioblastoma patients.
Elstner A, Stockhammer F, Nguyen-Dobinsky TN, Nguyen QL, Pilgermann I, Gill A, Guhr A, Zhang T, von Eckardstein K, Picht T, Veelken J, Martuza RL, von Deimling A, Kurtz A. Elstner A, et al. Among authors: von deimling a, von eckardstein k. J Neurooncol. 2011 Mar;102(1):71-80. doi: 10.1007/s11060-010-0284-8. Epub 2010 Jul 9. J Neurooncol. 2011. PMID: 20617365 Free PMC article.
838 results